OncoMatch/Clinical Trials/NCT06220188
PSMA-RLT in Biochemically Recurrent PCa
Is NCT06220188 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [177Lu]Lu-PSMA I&T for prostate cancer recurrent.
Treatment: [177Lu]Lu-PSMA I&T — Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA \> nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA PET negative for local recurrence
PSMA PET negative result for local recurrence
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical prostatectomy
biochemical recurrence after radical prostatectomy
Must have received: radiotherapy
biochemical recurrence after...radiotherapy
Cannot have received: hormonal therapy
Exception: no hormonal therapy within the last 12 months or recovered testosterone levels
No hormonal therapy within the last 12 months or recovered testosterone levels
Lab requirements
Blood counts
WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL
Kidney function
eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL
Patients must have adequate bone marrow reserve: WBC ≥1.5 x 10^9 /L, Platelets ≥100 x 10^9 /L and Haemoglobin ≥9 g/dL. Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify